Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: Implications for pre-exposure prophylaxis

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Chan, Philip A ^a   Huang, Austin ^a   Kantor, Rami ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Drug resistance; HIV; K65R; Non B subtypes; PrEP; Tenofovir

Indexed keywords

ARGININE; LYSINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; THYMIDINE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NUCLEOTIDE SEQUENCE; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEALTH; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; ORGANOPHOSPHONATES; POPULATION SURVEILLANCE; RNA-DIRECTED DNA POLYMERASE; WORLD HEALTH;

MLCS; MLOWN;

EID: 84877337392     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17701     Document Type: Article

References (20)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
2. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis. 2012;25:51-7.
3. Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46:719-25.
4. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156-64.
5. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS. 2008;22:2187-98.
6. Rhee S-Y, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA. 2006;103:17355-60.
7. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921-30.
8. Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22-33.
9. Chan PA, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 2009;3:447-65.
10. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9-13.
11. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2009;3:583-94.
12. Delong AK, Wu M, Bennett D, Parkin N, Wu Z, Hogan JW, et al. Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retrovir. 2012;28:894-901.
13. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24:1203-12.
14. Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, et al. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS ONE. 2011;6:e21189.
15. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis. 2006;194:651-60.
16. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS. 2007;21:665-75.
17. Sharma PL, Nettles JH, Feldman A, Rapp K, Schinazi RF. Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. Antivir Res. 2009;83:317-23.
18. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-13.
19. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa M-YS, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS. 2012;26:1679-84.
20. Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660-9.